Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Cell-Based Therapy for Glaucomatous Optic Nerve Degeneration

Cell-Based Therapy for Glaucomatous Optic Nerve Degeneration TRANSLATIONAL SCIENCE WITH CLINICAL PROMISE ONLINE FIRST Cell-Based Therapy for Glaucomatous Optic Nerve Degeneration LTHOUGH MEDICINE AND SURGERY THAT cesses in the optic nerve head, and retinal ganglion cell lowers intraocular pressure (IOP) are axon damage may be due to loss of metabolic support proven therapies for glaucoma, neither ap- following loss of contact with the astrocytes. Dai and co- proach is fully effective in all patients. The workers have suggested several potential explanations for A initial site of damage caused by in- the beneficial effects of olfactory ensheathing cells in this creased IOP is the region where unmyelinated axons of model: protection of axons (since the transplanted ol- the retinal ganglion cells pass through the optic nerve factory cells ensheathe the ganglion cell axons exposed head before becoming myelinated. In Translational Vi- by astrocyte retraction), protection of astrocytes (since sion Science and Technology, Dai and coworkers present transplanted olfactory cells reduce the extent of IOP- evidence that transplantation of autologous olfactory en- induced astrocyte retraction from the dorsal optic nerve sheathing cells into the optic nerve head provides a de- head sheath), and, least likely, reduction of IOP (the dif- gree of protection of the optic nerve against http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Ophthalmology American Medical Association

Cell-Based Therapy for Glaucomatous Optic Nerve Degeneration

JAMA Ophthalmology , Volume 130 (10) – Oct 1, 2012

Cell-Based Therapy for Glaucomatous Optic Nerve Degeneration

Abstract

TRANSLATIONAL SCIENCE WITH CLINICAL PROMISE ONLINE FIRST Cell-Based Therapy for Glaucomatous Optic Nerve Degeneration LTHOUGH MEDICINE AND SURGERY THAT cesses in the optic nerve head, and retinal ganglion cell lowers intraocular pressure (IOP) are axon damage may be due to loss of metabolic support proven therapies for glaucoma, neither ap- following loss of contact with the astrocytes. Dai and co- proach is fully effective in all patients. The workers have suggested several potential...
Loading next page...
 
/lp/american-medical-association/cell-based-therapy-for-glaucomatous-optic-nerve-degeneration-pU02mBa09e
Publisher
American Medical Association
Copyright
Copyright 2012 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6165
eISSN
2168-6173
DOI
10.1001/2012.jamaophthalmol.252
pmid
23044948
Publisher site
See Article on Publisher Site

Abstract

TRANSLATIONAL SCIENCE WITH CLINICAL PROMISE ONLINE FIRST Cell-Based Therapy for Glaucomatous Optic Nerve Degeneration LTHOUGH MEDICINE AND SURGERY THAT cesses in the optic nerve head, and retinal ganglion cell lowers intraocular pressure (IOP) are axon damage may be due to loss of metabolic support proven therapies for glaucoma, neither ap- following loss of contact with the astrocytes. Dai and co- proach is fully effective in all patients. The workers have suggested several potential explanations for A initial site of damage caused by in- the beneficial effects of olfactory ensheathing cells in this creased IOP is the region where unmyelinated axons of model: protection of axons (since the transplanted ol- the retinal ganglion cells pass through the optic nerve factory cells ensheathe the ganglion cell axons exposed head before becoming myelinated. In Translational Vi- by astrocyte retraction), protection of astrocytes (since sion Science and Technology, Dai and coworkers present transplanted olfactory cells reduce the extent of IOP- evidence that transplantation of autologous olfactory en- induced astrocyte retraction from the dorsal optic nerve sheathing cells into the optic nerve head provides a de- head sheath), and, least likely, reduction of IOP (the dif- gree of protection of the optic nerve against

Journal

JAMA OphthalmologyAmerican Medical Association

Published: Oct 1, 2012

References